Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib

Purpose: Yttrium-90 radioembolization (RE) is a locoregional therapy option for hepatocellular carcinoma (HCC). Sorafenib is a multikinase inhibitor used in HCC that can potentially affect the efficacy of RE by altering tumor vascularity or suppressing post-irradiation angiogenesis. The safety and e...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Rana, Nitesh, Ju, Andrew Wenhua, Bazylewicz, Michael, Kallakury, Bhaskar, He, Aiwu Ruth, Unger, Keith R., Lee, Justin S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2013
Konular:
Oncology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3874555/
https://ncbi.nlm.nih.gov/pubmed/24416722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2013.00323
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller